Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Operating Expenses (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of Operating Expenses readings, the most recent being $5.7 million for Q4 2025.

  • Quarterly Operating Expenses rose 57.77% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.1 million through Dec 2025, up 18.15% year-over-year, with the annual reading at $15.1 million for FY2025, 18.15% up from the prior year.
  • Operating Expenses hit $5.7 million in Q4 2025 for Oramed Pharmaceuticals, up from $2.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $21.0 million in Q3 2021 and bottomed at $2.4 million in Q3 2025.
  • Average Operating Expenses over 5 years is $6.4 million, with a median of $4.3 million recorded in 2023.
  • The largest annual shift saw Operating Expenses plummeted 67.04% in 2023 before it surged 57.77% in 2025.
  • Oramed Pharmaceuticals' Operating Expenses stood at $21.0 million in 2021, then plummeted by 43.96% to $11.8 million in 2022, then plummeted by 67.04% to $3.9 million in 2023, then decreased by 7.27% to $3.6 million in 2024, then surged by 57.77% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Operating Expenses are $5.7 million (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025).